$Vertex Pharmaceuticals (VRTX.US)$am watching this one to see the outcome biopharmcatalys... has options “Suzetrigine: The FDA has assigned a PDUFA target action date of January 30, 2025, for suzetrigine for the treatment of moderate-to-severe acute pain. Suzetrigine was granted Priority Review by the FDA. The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act became effective on January 1st, 2025. The NOPAIN Act mandates that Medicare provide a separate add-on payment in the hospital outp...
“SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-Opioid Treatments for Pain. SiteOne’s efforts in non-opioid pain management put it in a unique position relative to Vertex Pharmaceuticals, a major player in the field known for its successful development of cystic fibrosis treatments. Vertex has also been working on non-opioid pain drugs, specifically targeting the NaV1.8 sodium channel, a focal point shared by SiteOne’s lead pro...
In the end, a week that starts with an all-time high for the S&P 500, Dow Jones, and Nasdaq 100, ended with equities lower. At 4:02 p.m. ET, the three indices closed lower. The$Dow Jones Industrial Average (.DJI.US)$was off 0.70%, losing 300 points. The$S&P 500 Index (.SPX.US)$was down 1.32% and the$Nasdaq Composite Index (.IXIC.US)$was off 2.24%. MACRO In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
You will not get through the trading day without the news and animal spirits guiding the market. It is finally Friday, November 15th. My name is Kevin Travers and the market is falling today- here is why. $Alibaba (BABA.US)$shares declined after a report from the firm Friday morning that it was facing a consumer demand slump, even though its AI cloud business grew 7% to $4.2B in its second fiscal quarter. $Applied Materials (AMAT.US)$fell 8% after r...
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Vertex Pharmaceuticals Stock Forum
Revolutionary Gene Therapy CASGEVY Now Available Through NHS England: Major Win for Sickle Cell Patients
FDA Approves First Non-Opioid Pain Drug in 20 Years: Vertex's Game-Changing Alternative to Opioids
has options
“Suzetrigine: The FDA has assigned a PDUFA target action date of January 30, 2025, for suzetrigine for the treatment of moderate-to-severe acute pain. Suzetrigine was granted Priority Review by the FDA.
The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act became effective on January 1st, 2025. The NOPAIN Act mandates that Medicare provide a separate add-on payment in the hospital outp...
nfa
SiteOne’s efforts in non-opioid pain management put it in a unique position relative to Vertex Pharmaceuticals, a major player in the field known for its successful development of cystic fibrosis treatments. Vertex has also been working on non-opioid pain drugs, specifically targeting the NaV1.8 sodium channel, a focal point shared by SiteOne’s lead pro...
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
My name is Kevin Travers and the market is falling today- here is why.
$Alibaba (BABA.US)$ shares declined after a report from the firm Friday morning that it was facing a consumer demand slump, even though its AI cloud business grew 7% to $4.2B in its second fiscal quarter.
$Applied Materials (AMAT.US)$ fell 8% after r...
No comment yet